Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04285814 · ClinicalTrials.gov registry record
Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
A clinical trial of Genetic Disease and Prenatal Diagnosis, sponsored by Columbia University.
- Completed
- Registry status
- 33
- Enrollment target
- 2
- Study locations
NCT04285814: Completed study of Genetic Disease and Prenatal Diagnosis, sponsored by Columbia University.
NCT04285814 is a study of Genetic Disease and Prenatal Diagnosis that has completed, run by Columbia University. The registered enrollment target is 33 participants, below the 2,560-participant average among 30 other Genetic Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04285814, a study of Genetic Disease and Prenatal Diagnosis, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
Amniocentesis (amnio) and chorionic villus sampling (CVS) can reliably detect many smaller DNA/genetic abnormalities that cannot be reliably diagnosed by cell-free noninvasive prenatal testing (NIPT) that is in widespread use. The investigators present evidence that a cell-based form of NIPT, here called Single Fetal Cell (SFC) testing, using a blood sample from the mother can detect most or all of the genetic abnormalities that are detected using amnio or CVS. This study proposes to compare the effectiveness of SFC testing in detecting abnormalities already detected by amnio or CVS in women already undergoing these tests as part of their clinical care because of fetal ultrasound abnormalities.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Whole Fetal Cell (WFC) Testing
Study Locations (2)
New York
- Columbia University - New York
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2023-07-20 |
What the finished NCT04285814 record still lists
NCT04285814 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 2,560-participant average among 30 other Genetic Disease trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which Whole Fetal Cell (WFC) Testing is the first listed.
NCT04285814 reports a single indexed study location in New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04285814 about?
NCT04285814 is a clinical study titled "Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood". Amniocentesis (amnio) and chorionic villus sampling (CVS) can reliably detect many smaller DNA/genetic abnormalities that cannot be reliably diagnosed by cell-free noninvasive prenatal testing (NIPT) that is in widespread use. The investigators present evidence that a cell-based form of NIPT, here c...
What is the current status of trial NCT04285814?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2020-09-01. Estimated completion is 2023-07-20.
What conditions does trial NCT04285814 study?
This clinical trial studies the following conditions: Genetic Disease, Prenatal Diagnosis, Copy Number Abnormality.
What interventions are being tested in trial NCT04285814?
The interventions under investigation include: Whole Fetal Cell (WFC) Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04285814?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04285814 being conducted?
This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04285814's enrollment target sits among peer trials
33 26th of 30 higher than 5 of 30 other Genetic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Natural History Study of Patients with HPDL Mutations
RECRUITING
-
Diagnostic Odyssey: Whole Genome Sequencing (WGS)
RECRUITING
-
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI